Molecules Drugs And Research Laboratory Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 15-12-2024
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.53 M
as on 15-12-2024
- Satisfied Charges ₹ 1.20 Cr
as on 15-12-2024
- Revenue -98.54%
(FY 2020)
- Profit 95.30%
(FY 2020)
- Ebitda 100.00%
(FY 2020)
- Net Worth -5.59%
(FY 2020)
- Total Assets -5.79%
(FY 2020)
About Molecules Drugs And Research Laboratory
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹9.53 M. The company has closed loans amounting to ₹1.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
Durai Murugesan, Asaraf Ali, and Ganesan Sureshpandian serve as directors at the Company.
- CIN/LLPIN
U24100TN2009PTC070500
- Company No.
070500
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Molecules Drugs And Research Laboratory Private Limited offer?
Molecules Drugs And Research Laboratory Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services, Pharma & Bioanalytical Services, Pharmaceutical Services, Copyright & Trademark, Trademarks Services.
Who are the key members and board of directors at Molecules Drugs And Research Laboratory?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Durai Murugesan  | Director | 16-Jan-2009 | Current |
| Asaraf Ali | Director | 17-Nov-2009 | Current |
| Ganesan Sureshpandian | Director | 17-Nov-2009 | Current |
Financial Performance of Molecules Drugs And Research Laboratory.
Molecules Drugs And Research Laboratory Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 98.54% decrease. The company also saw a substantial improvement in profitability, with a 95.3% increase in profit. The company's net worth dipped by a decrease of 5.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Molecules Drugs And Research Laboratory?
In 2020, Molecules Drugs And Research Laboratory had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 30 Mar 2010 | ₹9.53 M | Open |
Indian Bank Creation Date: 28 Jan 2016 | ₹1.20 Cr | Satisfied |
How Many Employees Work at Molecules Drugs And Research Laboratory?
Unlock and access historical data on people associated with Molecules Drugs And Research Laboratory, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Molecules Drugs And Research Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Molecules Drugs And Research Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
